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Abstract
Background: Multiple candidate regions as sites for Schizophrenia and Bipolar susceptibility genes
have been reported, suggesting heterogeneity of susceptibility genes or oligogenic inheritance.
Linkage analysis has suggested chromosome 13q32 as one of the regions with evidence of linkage
to Schizophrenia and, separately, to Bipolar disorder (BP). SLC15A1 and GPC5 are two of the
candidate genes within an approximately 10-cM region of linkage on chromosome 13q32. In order
to identify a possible role for these candidates as susceptibility genes, we performed mutation
screening on the coding regions of these two genes in 7 families (n-20) affected with Bipolar
disorder showing linkage to 13q32.
Results:  Genomic organization revealed 23 exons in SLC15A1 and 8 exons in GPC5 gene
respectively. Sequencing of the exons did not reveal mutations in the GPC5 gene in the 7 families
affected with BP. Two polymorphic variants were discovered in the SLC15A1 gene. One was T to
C substitution in the third position of codon encoding alanine at 1403 position of mRNA in exon
17, and the other was A to G substitution in the untranslated region at position 2242 of mRNA in
exon 23.
Conclusions: Mutation analysis of 2 candidate genes for Bipolar disorder on chromosome 13q32
did not identify any potentially causative mutations within the coding regions or splice junctions of
the SLC15A1 or GPC5 genes in 7 families showing linkage to 13q32. Further studies of the
regulatory regions are needed to completely exclude these genes as causative for Bipolar disorder.
Background
Schizophrenia and associated mental illness are complex
psychiatric disorders each affecting about 1% of the world
population. Genetic evaluation of Schizophrenia and as-
sociated mental illness have suggested an important role
for genetic factors [1–4], however, no specific gene or bi-
Published: 22 October 2002
BMC Genomics 2002, 3:30
Received: 22 July 2002
Accepted: 22 October 2002
This article is available from: http://www.biomedcentral.com/1471-2164/3/30
© 2002 Maheshwari et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in 
all media for any purpose, provided this notice is preserved along with the article's original URL.BMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/30
Page 2 of 7
(page number not for citation purposes)
ological marker has yet been identified. Genome scans
have mapped several loci in various ethnic groups. Repli-
cations of these scans were positive in some cases and neg-
ative in others [2,5,6]. These data as well as reports of the
specific candidate genes beginning to be identified impli-
cate genetic heterogeneity of susceptibility genes [7,8] and
also sex specific differences [9] in the molecular basis of
disease phenotype. Linkage analyses of all published ge-
nome scans, for Schizophrenia genes, have identified
chromosome 13q32 as one of the regions with evidence
of linkage to Schizophrenia. In independent genome
scans, Bipolar disorder has also shown linkage to this re-
gion [10–13]. The linkage region for both disorders spans
approximately 10 cM on chromosome 13q32-q33 [14].
The region between D13 S71 and D13S274 showed link-
age to Bipolar disorder based on a whole genome scan
with an average marker spacing of ~6 cM on 13q32. Fine
mapping of this region, using nine additional markers,
with an average spacing of 0.9 cM confirms the evidence
of linkage to 13q32 around markers D13S79-D13S225
[15]. Association analyses with GASSOC TDT and ASPEX
/Sib_tdt showed linkage disequilibrium signals with sev-
eral markers, including D13S280 which need follow up
by typing more markers in the region in a larger sample
size [15]. Meta analysis of whole-genome linkage scans
further strengthens the susceptibility locus of BP on chro-
mosome 13q32 [13]. All these studies clearly point to-
wards further efforts in the identification of susceptibility
genes for this disorder. Based on evidence of linkage, a
comprehensive linkage map was developed around this
region [14]. Complete annotation of this region may in-
clude as many as 200 genes. One approach to identify sus-
ceptibility locus is to use the candidate gene approach.
Studies are underway at our center to identify susceptibil-
ity variants by mutation screening of candidate genes in
this region on a small series of Bipolar families showing
linkage to 13q32. For the present study we have selected
two candidate genes viz. human peptide transporter
(SLC15A1) and human glypican5 (GPC5) for mutation
screening from this region.
SLC15A1 is an intestinal oligopeptide transporter also re-
ferred to as HPEPT1 that belongs to solute carrier
family15. It is expressed in intestine, kidney, liver and
brain [16]. The function of SLC15A1 is to absorb and
transport small peptides [17,18]. The efficiency of absorp-
tion and transportation of L DOPA and its metabolite
dopamine, which are neurotransmitter candidates, is in-
creased by SLC15A1 [19]. Therefore, it is an important po-
tential gene for future drug design, delivery, and targeting
[20].
GPC5 belongs to the cell surface heparan sulfate prote-
oglycan family and is expressed in limb, kidney, develop-
ing central nervous system and brain tissue [21,22]. In
vertebrates 6 glypican family members belonging to the
proteoglycan family have so far been characterized [23].
Although there is a high degree of conservation of
polypeptide sequence among family members, they are
localized to different chromosomes. Glypican5 is structur-
ally correlated to glypican3 and localized to chromosome
13q32. Deletion of the 13q region is associated with hu-
man 13q syndrome, a developmental disorder [24]. Some
of the proteoglycans play important functional roles in
neurogenesis, axon guidance, synapse development [25],
and cellular growth and differentiation [26,27,23]. Muta-
tions in GPC3 cause Simpson-Golabi-Behmel syndrome
[28,29], however, no mutations were detected in the
GPC5 and GPC6 genes [30]. The glypican1 gene has been
suggested to be a good candidate for brachydactyly type E
[31]. Given that, GPC5 is highly expressed in brain and
mutations in other genes of the glypican families are asso-
ciated with developmental disorder; GPC5 could be a po-
tential candidate gene for Bipolar disorder.
In order to identify a possible role for these candidates
(SLC15A1 & GPC5) as susceptibility genes, we performed
mutation screening of the coding regions in 7 families (n
= 20) affected with Bipolar disorder showing linkage to
13q32. First, the accurate gene structure of SLC15A1 &
GPC5 was defined by analysis of the available draft hu-
man genomic sequence. Next, PCR primers and condi-
tions for amplification and sequencing of each exon were
developed and sequencing was performed.
Results
Genomic structure
We determined genomic structure of both the genes by
aligning cDNA sequences with available human draft ge-
nomic sequences http://www.ncbi.nlm.nih.gov/. The en-
tire SLC15A1 gene was represented in one BAC clone
sequence AL357553 and GPC5 in 6 BAC clone sequences.
Alignment of SLC15A1 cDNA sequence (accession
number U21936) with the genomic sequence (accession
no. AL357553) revealed that it is a large gene with a cod-
ing sequence of 3105 bp long, having 23 exons spread
over ~68.85 kb of genomic sequence. The splice junctions
follow the GT/AG rule (Table 1).
Alignment of GPC5 cDNA (accession number U66033)
with the working draft sequence revealed a genomic or-
ganization of 8 exons, which was represented in 6 BAC
clone sequences. The coding sequence of GPC5 gene is
2558 bp long and encodes 572 amino acids. The first two
exons of the GPC5 gene are present in BAC clone acces-
sion number AL138714, exons 3,4,5 in AC027429, exon
6 in AL162456, exon 7 in AL163537 and exon 8 in
AL157363 (Table 2). Most of the splice junctions follow
the GT/AG rule.BMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/30
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Mutation analysis
No mutations were identified in the GPC5 gene in the 7
families affected with Bipolar disorder. Two polymorphic
variants were discovered in SLC15A1 gene, one in exon 17
and another one in exon 23. Sequence analysis revealed a
T to C (Figure 1A) substitution in third position of codon
encoding alanine at 1403 position of mRNA and A to G
(Figure 1B) substitution at position 2242 of mRNA. Of
these, 6 individuals (3 affected and 3 normal) were ho-
mozygous CC (exon 17), 15 (11 affected and 4 normal)
were heterozygous TC (exon 17) and three were hetero-
zygous AG (exon 23).
Discussion
Gene mapping studies using microsatellite markers have
identified chromosome 13q32 as one of the putative loci
for Schizophrenia and Bipolar disorder [10–13,15]. To
begin identification of a susceptibility gene for Bipolar
disorder, we have screened two candidate genes, SLC15A1
and GPC5, on the basis of their genetic localization within
the 10 cM region of chromosome 13q32 [14]. The entire
SLC15A1 gene was represented in one BAC clone se-
quence AL357553 and GPC5 in 6 BAC clone sequences.
Alignment of SLC15A1 cDNA sequence with genomic se-
quence (accession no. AL357553) revealed that it is a large
gene with a coding sequence of 3105 bp long, having 23
exons spread over ~68.85 kb of genomic sequence. The
splice junctions follow the GT/AG rule (Table 1). A wide
variety of transporters are found in the intestine and sev-
eral genetic disorders have been shown to result from de-
ficient intestinal transporters [20]. SLC15A1 consists of
708 amino acids with putative 12 transmembrane do-
mains and 2 putative protein kinase C phosphorylation
sites. Exon-intron boundaries occur mostly in the loops
connecting transmembrane segments [32] suggesting a
modular gene structure reflecting the TMS-loop repeat
units in SLC15A1. Computer modeling and site directed
mutagenesis studies suggested a list of amino acids for the
transport functional activities. Tyrosine (Y167) and histi-
dyl residues (H57, H111 and H121) are two of these ami-
no acids playing important roles in the function of
transporters [33–36]. In our mutation screening of fami-
lies with Bipolar disorder we did not find variants at these
positions. However, we did identify two variants in the
SLC15A1 gene, one in exon 17 and another one in exon
23. Sequence analysis revealed a T to C substitution in the
third position of codon encoding alanine at 1403 posi-
tion (exon 17) of mRNA. Of these, 6 individuals were ho-
mozygous CC (29%) and 15 were heterozygous TC (71%)
(exon 17). However, there was no amino acid change.
Substitution of T to C in normal members as well, sug-
gests it is a polymorphic variant and not a pathogenic mu-
Table 1: Genomic structure of human peptide transporter (SLC15A1) showingnumber of exons, cDNA position, exon size, exon-intron 
junctions, 3' & 5' intron acceptor & donor sites, intron size and intron phase.
Exon cDNA bp 
Position
Exon Size Intron-Exon Junctions Intron Size bp Intron Phase
Intron 3' Exon Intron 5'
12 – 6 1 6 1 CACCTG...CCATGGgtacgctc >25 kb 1
2 61–77 16 tcttttagGAATGTTCACACgtgagtac 394 2
3 78–159 81 tgtcgaAGTTTCTTT...TGCGAGgtaactgta 102 1
4 158–302 144 tgcaaaagCAATCC...GTTCAAgtgagtgc 2091 2
5 302–422 120 aaacacagGACCAT..GCACGTgtgagttg 2008 2
6 422–522 100 tttcccagGGTGCT...GGCCAGgtaagggt 215 0
7 519–611 92 cattgcagGAGAAA...TCAGAGgtaagaga 2173 2
8 611–696 85 ctccccagTTCAAC...CCCTGAgtaagtgg 3277 1
9 697–779 82 ctatctagTTGTGT.....ATCGGTgtaagtat 3294 0
10 780–867 87 ttccttcagTTTGCC...TACGATgtaagtaac 554 0
11 867–957 90 aactacagGAGCGG...CAGCAGgtaatgtg 1940 0
12 955–1002 47 atttttaagGGCTCC...GAAATCgtaagtttg 92 0
13 1002–1034 32 tctttttagGGAGCTATGCAGgtagaagac 77 0
14 1030–1123 93 cctctgcagACCGTG...TTTCAC gtaggttga 801 2
15 1120–1205 85 tgccatcagCTCCTT...ATCGATgtgagttgt 2433 0
16 1206–1325 119 tttgctcagAAAACT...TCTCAAgtaagtaga 1699 0
17 1326–1476 150 ctctatagACAAAT...CAGGTGgtaagtgtg 1755 2
18 1472–1522 50 tctctcagGTAAAG...AATCAGgtatgtata >13 kb 2
19 1519–1630 111 tgtttcagATTTGT.....TGGCATgtaagtac 114 2
20 1631–1739 108 tttgatagAAAAGG...AGGAAGgttagtaa 522 0
21 1738–1884 146 tgctgcagAATGAC....TCTCAGgtttcttg 1279 0
22 1879–1991 112 ttcctcagGCTCCT...AAACAGgtatggcg 1273 0
23 1990–3105 1115 cttcaaagTGGGCC...CTGTTCTTABMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/30
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tation. In exon 23, the variation observed was an A to G
substitution in the untranslated region at position 2242 of
mRNA. Of these, eighteen were homozygous AA (86%)
and three were heterozygous AG (14%). The variant in
exon 17 was also found in the SNP database (NCBI SNP
cluster ID rs1339067) although the population frequency
was not reported. An association study of this variant in a
large population will aid in understanding the potential
role of the SLC15A1 gene in Bipolar disorder.
Alignment of the GPC5 cDNA with the working draft se-
quence revealed a genomic organization of 8 exons,
which was represented in 6 BAC clone sequences (Table
2). The whole GPC5 gene is 2558 bp long and encodes
572 amino acids. The first two exons of the GPC5 gene are
present in BAC clone accession number AL138714, exons
3,4,5 in AC027429, exon 6 in AL162456, exon 7 in
AL163537 and exon 8 in AL157363 (Table 2). Most of the
splice junctions follow the GT/AG rule. The exon structure
was confirmed by comparing the cDNA with nucleotide
contig NT_009866. While we finished screening this gene
for mutations, its genomic structure was published and
confirms the presence of 8 exons with exon/intron bound-
aries following the AG/GT rule with a size of approximate-
ly 2 Mb [30]. No mutations or polymorphisms were
identified in the GPC5 gene in the 7 families affected with
Bipolar disorder decreasing the likelihood that this gene is
involved in the etiology of Bipolar disorder. Several disor-
ders have been reported due to mutations in glypican gene
families [31,37] and interestingly due to deletion of re-
gion on chr.13 q32 [24,38]. It would be interesting to
study the occurrence of Schizophrenia or other associated
mental illnesses in individuals with these deletions. Muta-
tion screening of the glypican genes in these patients
might give clue to Schizophrenia susceptibility locus.
Absence of pathogenic mutations in the two genes GPC5
and SLC15A1 studied in seven families of Bipolar disorder
suggests that these genes are presumably not involved in
the susceptibility locus for Bipolar disorder in the families
screened. However, due to the complex nature of these
diseases, no definite conclusions can be drawn. We can-
not rule out genetic heterogeneity for these genes and sug-
gest studying more families. For example, the NOTCH 4
gene that is located on chromosome 6p21.3 confers sus-
ceptibility to Schizophrenia in the British population but
not in the Japanese population [39]. Genetic heterogene-
ity is very common in hereditary deafness [40]; also the
prevalence of mutations in the connexin 26 gene is a ma-
jor cause of non-syndromic autosomal recessive deafness
that varies in different populations [41].
Table 2: Genomic structure of human glypican5 (GPC5) showing number of exons, cDNA position, BAC clones representing genomic 
sequence, exon-intron junctions, 3' & 5' intron acceptor & donor sites, intron phase and exon size.
Exon cDNA bp 
position
BAC clone Intron-Exon Junctions Intron phase Exon size
Intron 3'
acceptor
Exon Intron 5'
donor
1 1–178 AL138714 GACGGC...GGGCAGgtaagggg 1 177
2 175–339 AL138714 gtgttccagGACCTG..TTCAAGgtggatct 1 164
3 338–1044 AC027429 tgttacagAAACCC...GAACAGgtaagtag 0 706
4 1033–1168 AC027429 tttaaaagGTAAAT...AAGAAAgtaagaca 1 135
5 1169–1294 AC027429 tcatttagAGAATT...AAAAAGgtatttta 2 129
6 1293–1415 AL162456 cttgctagTTATAC...GTTCAGgtaagtcc 0 122
7 1414–1576 AL163537 acaattagTTGTTA...CAGACTgtaagtgt 1 162
8 1576–2526 AL157363 ctctacagGGATGCC...TGGTGG 950
Figure 1
Sequencing traces demonstrating polymorphic variants in 
exon 17(T→C) and exon 23 (A→G) of SLC15A1 gene. Exon 
17 A: Homozygous CC, Exon 17 B: Heterozygous TC, Exon 
23 A: Homozygous AA, Exon 23 B: Heterozygous AG.BMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/30
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Considering the complex nature of the disease and the
supportive evidence of linkage to chromosome 13q32
[13,15] it would be worth while to continue further stud-
ies to find out Schizophrenia susceptibility genes at this
critical region. As the human genome reference sequence
is nearing completion, the analysis of genetic variation is
becoming important. Our plans are to annotate all the
genes for a 10-mega base region on chromosome 13 and
develop a high density SNP map. Aim is to identify vari-
ants in the critical region, to predict haplotypes from nu-
merous variants observed and perform mutation analysis
by direct sequencing with the ultimate objective of identi-
fying specific sequence/haplotype associated with the dis-
ease phenotype.
Methods
Study Subjects
A total of 7 nuclear families (n-20) affected with Bipolar
disorder were selected. The seven families consist of five
normal parents, five affected parents, seven affected pa-
tients, one normal sib and two affected members. These
families were selected from four known pedigree series
with evidence of linkage to chromosome 13q32[15].
Genomic structure determination
The genomic structures of SLC15A1 (accession number
U21936) and GPC5 (accession number U66033) were de-
termined by direct comparison of their full-length cDNA
with the sequence of human chromosome 13 genomic
Table 3: Human peptide transporter (SLC15A1) : PCR Primers and Annealing temperature
Exon cDNA bp Position Forward Primer
Primer sequence 5' → 3'
Reverse Primer
 Primer sequence 5' → 3'
Product Size bp Annealing 
Temp.
2 61–77 P17 ccctctgaccaccctaaaaa tgaacccttaggggtaaaaca 191 60
3 78–159 P1 tggggaaggattagtgtaggg aactttcccagccacgagt 498 60
4 158–302
5 302–422 P2 tgtggtggagtcaaaagtgg cctgaagacccagctcaatc 356 60
6 422–522 P3 gtcactatgccaggcccact gcctctgactcctggatgtg 258 60
7 519–611 P18 agtggattgatagccaaagtcatct aagacacggacttggcctta 200 60
8 611–696 P4 tgtgaaagcaatacgtaattatcag ctactttttgttgccacttgttacat 295 60
9 697–779 P16 tcaagagccatttctattcttcc gcatctctctaggccacagg 350 48
10 780–867 P5 tgaaatgtgcttccctgaca tcactgaccattttgtccatgt 254 60
11 867–957 P6 acctcccagcttgcctcta tgaagtgagccttggtacctg 293 60
12 955–1002 P7 cagggtactgctttgtgcag tatcctctaggcgaggttgc 701 60
13 1002–1034
14 1030–1123
15 1124–1205 P8 aagatggggagaggtgcttt gctccagggctcagtttaca 348 60
16 1206–1325 P9 aggtctgtgattggcagctt gctggccttggcatttatac 379 60
17 1326–1476 P10 aaacctcatgacggtgtctg ttttggcctccagtatcaca 400 60
18 1472–1522 P11 gcctccagagcccttctaat tcagccagccttacattgct 331 60
19 1519–1630 P12 gacattgtggcggaatctct gggagtattgcccaacttca 356 60
20 1631–1739
21 1738–1884 P13 gtcccatcagcattttctgc ggtcaaactcaatttacctgttcg 292 60
22 1879–1991 P14 ccatgatgaccatgaacagg cattgaggccacctgacttt 299 60
23 1993–2315 P15 ccaagaacatgtacgcacca aggctgaggcaggagaatta 540 60
Table 4: Human glypican5 (GPC5) : PCR Primers and Annealing temperature
Exon cDNA U66033 Forward Primer 5' → 3' Reverse Primer 5' → 3' Product Size Annealing 
Temperature
1 1–178 cgctgtgtcttccacgtct ctacccgcaccaagcatc 410 60 (5%DMSO)
2 175–339 gtgcaggactggtcataacg gtttccccaatccaactcag 455 60
3 338–1044 agcagatggacggtgttagc caagaagtcagactgaaaatgtg 797 60 (DT)
4 1033–1168 gcataccacataaatgtccatga ggcttactttcttttctctttctgg 408 60
5 1169–1294 ttgatggcctttattgtgga tcaggttttgttgttcttttcc 352 48
6 1293–1415 gaggaaattccgacctcaaa cactgcatattgactgcatcc 401 60
7 1414–1576 ccatttccaattcctcttgc tgtaagactttgcccgctatt 466 60BMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/30
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clones retrieved from the GenBank htgs database http://
www.ncbi.nlm.nih.gov/ by BLASTN searching. Intronic
oligonucleotide primer pairs flanking the coding frag-
ments were designed for both the genes using program
primer 3 http://www.genome.wi.mit.edu/cgi-bin/primer/
primer3.cgi using the genomic sequences of SLC15A1 and
GPC5 gene respectively.
Mutation analysis
Mutation screening of the coding region of the genes for
sequence variants was performed by PCR amplification of
20 samples of 7 BP families and a control sample. Each
sample was analyzed for exon 2–23 of the SLC15A1 gene
(Table 3) and 7 coding fragments of the GPC5 gene (Table
4). Twenty two fragments of the SLC15A1 gene were am-
plified in eighteen reactions P1-P18 (Table 3). PCR reac-
tions were carried out under the standard PCR conditions.
In brief each 50-ul reaction contained 50 ng of genomic
DNA, 20 pmole of each primer, 1 unit of AmpliTaq Gold
DNA polymerase, 5 ul of 10 X buffer, 2.5 ul of 2.5 mM of
MgCl2 & 2.5 mM of dNTPs. Amplification conditions
were 94°C/ 12 min, 45 cycles of 94°C/30 s, 60°C/ 30 s,
70°C/ 90 s followed by final extension step of 70°C/ 5
min. Sequences of the primers and annealing temperature
of each amplification are given in Tables 3 &4. PCR prod-
ucts were analyzed using 2% agarose gel electrophoresis
and purified by 96 well Qia Quick PCR purification kit
(Qiagen). Sequencing of each exon except exon 3 of GPC5
was performed using BODIPY dye primer chemistry [42]
on an ABI 3700 DNA sequencer (Applied Biosystems, Fos-
ter City, CA, USA). Exon 3 of GPC 5 was sequenced with
ABI Big Dye terminator chemistry. The obtained sequenc-
es were compared with the corresponding control gene se-
quences using SEQUENCHER software (Gene codes
corporation, Ann Arbor, MI, USA).
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Addendum
While screening an additional three families, and reanaly-
sis of our previous families we noted two variants in exon
three: One was A155V (C>T) and second was R223C
(C>T). Of the 23 subjects studied, 5 (3 affected and 2 nor-
mal) were heterozygous Ala/Val. 1 (affected) homozygous
Val/Val and 17 (13 affected and 4 normal) were ho-
mozygous Ala/Ala. The second variant R223C was ob-
served in 2 (1 affected and 1 normal) subjects, both were
heterozygous Arg/Cys, 16 affected and 5 normal subjects
were homozygous Arg/Arg and none were Cys/Cys ho-
mozygous. An association study of the variants detected in
GPC5 and SLC15A1 genes in a large gene population will
aid in understanding the potential role of these genes in
Bipolar disorders.
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